HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

by NASDAQ Market News September 13, 2021

NASDAQ Market News
Click here to email author

Yamana Gold Reports Positive Initial Exploration Drill Results at Wasamac; Provides an Update on Its Generative Exploration Program, Which Continues to Show Significant Progress of Both Advanced and Early Stage Exploration Projects

Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

Ads